National Cancer Institute National Cancer Institute
U.S. National Institutes of Health National Cancer Institute
NCI Home Cancer Topics Clinical Trials Cancer Statistics Research & Funding News About NCI
Cancell/Cantron/Protocel (PDQ®)
Patient VersionHealth Professional VersionLast Modified: 07/23/2009



Purpose of This PDQ Summary






Overview






General Information






History






Laboratory/Animal/Preclinical Studies






Human/Clinical Studies







Adverse Effects






Overall Level of Evidence for Cancell/Cantron/Protocel






Appendix






Changes to This Summary (07/23/2009)






More Information



Page Options
Print This Page  Print This Page
Print This Document  Print Entire Document
View Entire Document  View Entire Document
E-Mail This Document  E-Mail This Document
Quick Links
Director's Corner

Dictionary of Cancer Terms

NCI Drug Dictionary

Funding Opportunities

NCI Publications

Advisory Boards and Groups

Science Serving People

Español
Quit Smoking Today
NCI Highlights
Office of Biorepositories and Biospecimen Research

The Nation's Investment in Cancer Research FY 2010

Report to Nation Finds Declines in Cancer Incidence, Death Rates
Adverse Effects

The reported side effects of Cancell/Cantron/Protocel include temporary, moderate fatigue during the first few weeks of treatment and nausea. Reviewed in [1,2] One patient who exceeded the manufacturer’s dose recommendations experienced diarrhea for a few hours but was reported to be fine the next day. Reviewed in [2]

References

  1. Questionable methods of cancer management: Cancell/Entelev. CA Cancer J Clin 43 (1): 57-62, 1993 Jan-Feb.  [PUBMED Abstract]

  2. Cancell Alternative Cancer Treatment. Available online. Last accessed June 16, 2009. 

Back to TopBack to Top

< Previous Section  |  Next Section >


A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov